The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices
Open accessAbstract
On August 13, 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) among adults aged ≥65 years. PCV13 should be administered in series with the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax23, Merck & Co., Inc.]), the vaccine currently recommended for adults aged ≥65 years. PCV13 was approved by the Food and Drug Administration (FDA) in late 2011 for use among adults aged ≥50 years. In June 2014, the results of a randomized placebo-controlled trial evaluating efficacy of PCV13 for preventing community-acquired pneumonia among approximately 85,000 adults aged ≥65 years with no prior pneumococcal vaccination history (CAPiTA trial) became available and were presented to ACIP. The evidence supporting PCV13 vaccination of adults was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and determined to be type 2 (moderate level of evidence); the recommendation was categorized as a Category A recommendation. This report outlines the new recommendations for PCV13 use, provides guidance for use of PCV13 and PPSV23 among adults aged ≥65 years, and summarizes the evidence considered by ACIP to make this recommendation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
Bonten, M. J. M., Huijts, S. M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., van Werkhoven, C. H., van Deursen, A. M. M., Sanders, E. A. M., Verheij, T. J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408544 · Cited by 1,248 · cited 3×
“PCV13 efficacy was not demonstrated against PCV13-type or allcause mortality (6); no studies evaluating PCV13 effectiveness against mortality were identified.”
Background(2013) · American Journal of Transplantation · doi:10.1111/ajt.12073 · Cited by 687
Nuorti, J. P., & Whitney, C. G. (2010) · MMWR Morbidity and Mortality Weekly Report · Cited by 456
Jackson, L. A., Gurtman, A., van Cleeff, M., Jansen, K. U., Jayawardene, D., Devlin, C., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.085 · Cited by 232
Kobayashi, M., Bennett, N. M., Gierke, R., Almendares, O., Moore, M. R., Whitney, C. G., & Pilishvili, T. (2015) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6434a4 · Cited by 219
Self-citationJackson, L. A., Gurtman, A., Rice, K., Pauksens, K., Greenberg, R. N., Jones, T. R., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.010 · Cited by 188
Jackson, L. A., Gurtman, A., van Cleeff, M., Frenck, R. W., Treanor, J., Jansen, K. U., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.04.084 · Cited by 165
Greenberg, R. N., Gurtman, A., Frenck, R. W., Strout, C., Jansen, K. U., Trammel, J., Scott, D. A., Emini, E. A., Gruber, W. C., & Schmoele-Thoma, B. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.002 · Cited by 163
McLaughlin, J. M., Jiang, Q., Isturiz, R. E., Sings, H. L., Swerdlow, D. L., Gessner, B. D., Carrico, R. M., Peyrani, P., Wiemken, T. L., Mattingly, W. A., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy312 · Cited by 159
Goldblatt, D., Southern, J., Andrews, N. J., Ashton, L., Burbidge, P., Woodgate, S., Pebody, R. G., & Miller, E. (2009) · Clinical Infectious Diseases · doi:10.1086/606046 · Cited by 150
Tsaban, G., & Ben‐Shimol, S. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.032 · Cited by 127
Schwarz, T. F., Flamaing, J., Rümke, H. C., Pénzes, J., Juergens, C., Wenz, A., Jayawardene, D. A., Giardina, P. C., Emini, E. A., Gruber, W. C., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.031 · Cited by 94
Stoecker, C., Kim, L., Gierke, R., & Pilishvili, T. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3651-0 · Cited by 93
Self-citationAhmed, S. S., Pondo, T., Xing, W., McGee, L., Farley, M. M., Schaffner, W., Thomas, A. R., Reingold, A. L., Harrison, L. H., Lynfield, R., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz739 · Cited by 78
Self-citationMiernyk, K. M., Butler, J. C., BULKOW, L. R., Singleton, R. J., Hennessy, T. W., Dentinger, C., Peters, H. V., Knutsen, B., Hickel, J., & Parkinson, A. J. (2009) · Clinical Infectious Diseases · doi:10.1086/599824 · Cited by 75
Gessner, B. D., Jiang, Q. L., van Werkhoven, C. H., Sings, H. L., Webber, C., Scott, D. A., Neuzil, K. M., O’Brien, K. L., Wunderink, R. G., Grobbee, D. E., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.097 · Cited by 62
Shiramoto, M., Hanada, R., Juergens, C., Shoji, Y., Yoshida, M., Ballan, B., Cooper, D., Gruber, W. C., Scott, D. A., & Schmöele-Thoma, B. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1030550 · Cited by 46
Prato, R., Fortunato, F., Cappelli, M. G., Chironna, M., & Martinelli, D. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019034 · Cited by 33
Jackson, L. A., Sahly, H. M. E., George, S. L., Winokur, P. L., Edwards, K. M., Brady, R. C., Rouphael, N., Keitel, W. A., Mulligan, M. J., Burton, R. L., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.12.061 · Cited by 24
Pneumococcal Conjugate Vaccine Safety in Elderly Adults
Tseng, H. F., Sy, L. S., Qian, L., Liu, I.-L. A., Mercado, C., Lewin, B. J., Tartof, S. Y., Nelson, J. C., Jackson, L. A., Daley, M. F., et al. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy100 · Cited by 24
Tinoco, J. C., Juergens, C., Palacios, G. M. R., Vázquez-Narváez, J. A., Enkerlin, H. L., Sundaraiyer, V., Pathirana, S., Kalinina, E., Gruber, W. C., Scott, D. A., et al. (2014) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00711-14 · Cited by 21
Shiramoto, M., Irie, S., Juergens, C., Yamaji, M., Tamai, S., Aizawa, M., Belanger, T., Gruber, W. C., Scott, D. A., & Schmöele-Thoma, B. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28633 · Cited by 18
Haber, P., Arana, J., Pilishvili, T., Lewis, P., Moro, P. L., & Cano, M. V. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.052 · Cited by 15
Self-citation
Cited by
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
Jain, S., Self, W. H., Wunderink, R. G., Fakhran, S., Balk, R., Bramley, A. M., Reed, C., Grijalva, C. G., Anderson, E. J., Courtney, D. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500245 · Cited by 2,323
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Tunkel, A. R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S. L., Scheld, W. M., van de Beek, D., Bleck, T. P., Garton, H. J. L., & Zunt, J. R. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw861 · Cited by 1,067
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71081-3 · Cited by 733
Metadata
- Authors
- Matanock, A., Lee, G., Gierke, R., Kobayashi, M., Leidner, A., & Pilishvili, T.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2019-11-22
- Volume
- 68
- Issue
- 46
- Pages
- 1069-1075
- ISSN
- 0149-2195
- 1545-861X
- OpenAlex
- W2182945617
- Cited by
- 668
- References
- 26
- FWCI
- 57.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.